An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00337285 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

349

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder
Attention Deficit Disorders With Hyperactivity
Attention Deficit Hyperactivity Disorders

Interventions

DRUG: Vyvanse (lisdexamfetamine dimesylate), NRP104

Sponsor

New River Pharmaceuticals

Collaborators

[object Object]